30
Participants
Start Date
August 3, 2022
Primary Completion Date
August 3, 2025
Study Completion Date
August 3, 2027
Vγ2Vδ2 T lymphocyte-based immunotherapy
Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.
Treatment regimens for MDR-TB
Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
RECRUITING
Shanghai Pulmonary Hospital, Shanghai, China, Shanghai
RECRUITING
Shanghai Pulmonary Hospital, Shanghai
Shanghai Public Health Clinical Center
OTHER_GOV
Huashan Hospital
OTHER
No.85 Hospital, Changning, Shanghai, China
OTHER
Shanghai Pulmonary Hospital, Shanghai, China
OTHER